Progyny, Inc. Stock Price, News & Analysis

Progyny, Inc. (Nasdaq: PGNY) will report its financial results for Q1 2021 on May 6, 2021, after market close. The company specializes in fertility and family building benefits. A conference call will follow at 4:45 PM ET, with access details for both U.S. and international participants provided. An audio replay will be available until May 14, 2021. Progyny is recognized for its innovative approach in the fertility sector, supporting patients and employers alike. Further information can be found on their website.

Progyny, Inc. (Nasdaq: PGNY) reported a record revenue of $100.3 million for Q4 2020, a 54% increase from Q4 2019. For FY 2020, total revenue reached $344.9 million, up 50% year-over-year. The company also projected 2021 revenue between $520 million and $540 million, reflecting growth of 51% to 57%. Key highlights included a tripled Adjusted EBITDA and significant growth in both fertility and pharmacy benefit services. Despite challenges from the COVID-19 pandemic, Progyny's performance showcased its market resilience and expansion capabilities.

Progyny, a leader in fertility benefits management, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 8:40 A.M. ET. Chief Executive Officer David Schlanger and Chief Financial Officer Mark Livingston will engage in a fireside chat at the event. Interested parties can access the live audiocast and replay via Progyny’s website. The company is recognized for redefining fertility and family building solutions, benefiting employers and patients alike.

Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, will release its financial results for Q4 and full year 2020 on February 24, 2021, post-market. A conference call will follow at 4:45 PM ET, offering insights into the company's performance. Participants can join via specified dial-in numbers and passcodes, with a replay available until March 3, 2021. The firm emphasizes its innovative approach to fertility solutions, aiming to benefit employers, patients, and healthcare providers. Progyny has received accolades from various organizations, highlighting its industry leadership.

Progyny, a leading fertility benefits management company, announced that CEO David Schlanger will present at the 39th Annual JP Morgan Healthcare Conference on January 12, 2021, at 3:40 P.M. Eastern Time. Following the presentation, President and COO Pete Anevski and CFO Mark Livingston will join Schlanger for a breakout session. A live audiocast and replay will be available on Progyny's website. The company is dedicated to redefining fertility benefits, providing comprehensive solutions that benefit employers, patients, and healthcare providers.

Progyny (Nasdaq: PGNY) has announced the addition of two new board members: Malissia R. Clinton and Roger Holstein, effective November 16, 2020. Clinton, with over 25 years in various industries, will serve on the Nominating and Governance Committee, while Holstein, a healthcare industry veteran, will join the Compensation Committee. Their expertise in healthcare and technology aims to provide strategic guidance as Progyny transitions to a high-growth leader in fertility benefits management. The board now consists of nine directors, enhancing the company's governance and industry insights.

Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, announced that CEO David Schlanger will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference. The pre-recorded chat will be accessible from November 23 on Progyny’s website. Additionally, the company will conduct one-on-one meetings on December 1, with requests made exclusively through Piper Sandler. Progyny's innovative benefits solution aims to redefine fertility support, offering education, access to specialists, and improved clinical outcomes while reducing costs for employers.

Progyny, a leader in fertility benefits management, reported third quarter 2020 revenue of $98.9 million, up 62% from prior year. Net income hit $5.4 million, reversing an $8.2 million loss year-over-year. The company anticipates 2020 revenue guidance of $340-$345 million, targeting a growth of 48%-50%. For 2021, Progyny projects a minimum of $525 million in revenue with 180 clients covering 2.7 million lives. Adjusted EBITDA nearly doubled to $10.6 million, demonstrating strong operational leverage despite COVID-19.

Progyny, a leader in fertility benefits management, is scheduled to report its financial results for Q3 2020 on Nov. 5, 2020, after market close. A conference call will follow at 4:45 PM ET, accessible via specific dialing numbers for U.S. and international participants. An audio replay will be available until Nov. 12, 2020. Progyny is recognized for its innovative fertility solutions, enhancing access for patients while reducing healthcare costs for employers. With headquarters in New York, the company is gaining attention for its impact on fertility benefits.